Neuropsychological Assessment in Elderly Men with Benign Prostatic Hyperplasia Treated with Dutasteride

October 2018 in “ Clinical Drug Investigation ”

Antonino Catalano, Gabriella Martino, Federica Bellone, Maria Papalia, Carmen Lasco, Giorgio Basile, Alberto Sardella, Giacomo Nicocia, Nunziata Morabito, Antonino Lasco

dutasteride benign prostatic hyperplasia Avodart BPH

Studysummary This study observed that men receiving dutasteride for benign prostatic hyperplasia did not show significant differences in neuropsychological assessments compared to a control group not on dutasteride.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

The study examined the potential neuropsychological effects of dutasteride, a drug used to treat benign prostatic hyperplasia (BPH), on elderly men. It included 40 participants with an average age of 71.4 years, split into two groups: one receiving dutasteride and a control group not on the medication. After administering various neuropsychological tests, the researchers found no significant differences in outcomes between the two groups, suggesting that dutasteride does not cause neuropsychological impairment. Despite the study's small sample size and cross-sectional design, the findings indicate that dutasteride is mentally safe for treating BPH in elderly men, but further research is recommended to confirm these results.

View this study on link.springer.com →

Discuss this study in the Community →

Research cited in this study

11 / 11 results

research The Risk of Dementia with the Use of 5 Alpha Reductase Inhibitors

18 citations , June 2017 in “Journal of the neurological sciences”

In this study, the use of 5 alpha reductase inhibitors was associated with an increased risk of dementia during the first two years of treatment, but the risk was not significant with longer exposure.

research Neuroactive Steroid Levels and Psychiatric and Andrological Features in Post-Finasteride Patients

58 citations , April 2017 in “The Journal of Steroid Biochemistry and Molecular Biology”

This study found that patients with post-finasteride syndrome exhibited major depressive disorder, severe erectile dysfunction, and neuropathy, alongside altered neuroactive steroid levels in cerebrospinal fluid.

research Association of Suicidality and Depression With 5α-Reductase Inhibitors

90 citations , March 2017 in “JAMA Internal Medicine”

In this study, older men using 5α-reductase inhibitors for prostatic enlargement did not show increased risk of suicide, but had elevated risks of self-harm and depression.

research Adverse Effects of 5α-Reductase Inhibitors: What Do We Know, Don't Know, and Need to Know?

111 citations , August 2015 in “Reviews in Endocrine and Metabolic Disorders”

5α-reductase inhibitors may cause persistent sexual dysfunction and depression, needing more research on long-term effects.

Neuroactive Steroid Levels Are Modified in Cerebrospinal Fluid and Plasma of Post-Finasteride Patients Showing Persistent Sexual Side Effects and Anxious/Depressive Symptomatology

research Neuroactive Steroid Levels Are Modified in Cerebrospinal Fluid and Plasma of Post-Finasteride Patients Showing Persistent Sexual Side Effects and Anxious/Depressive Symptomatology

73 citations , July 2013 in “The Journal of Sexual Medicine”

This study observed that androgenic alopecia patients taking finasteride had altered neuroactive steroid levels and persistent depression symptoms even after stopping the treatment.

research Steroid 5α-Reductase as a Novel Therapeutic Target for Schizophrenia and Other Neuropsychiatric Disorders

72 citations , January 2011 in “Current Pharmaceutical Design”

This review discusses the potential role of steroid 5α-reductase inhibitors in treating neuropsychiatric disorders related to dopaminergic hyperreactivity but reports no new clinical results.

Adverse Side Effects of 5α-Reductase Inhibitors Therapy: Persistent Diminished Libido, Erectile Dysfunction, and Depression in a Subset of Patients

research Adverse Side Effects of 5α-Reductase Inhibitors Therapy: Persistent Diminished Libido, Erectile Dysfunction, and Depression in a Subset of Patients

223 citations , December 2010 in “The Journal of Sexual Medicine”

This review discusses persistent adverse effects of 5α‐reductase inhibitors, like diminished libido and erectile dysfunction, in some patients and highlights the need for patient discussions before therapy, especially for androgenetic alopecia.

research An Overview on 5α-Reductase Inhibitors

219 citations , October 2009 in “Steroids”

5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.

The Importance of Dual 5α-Reductase Inhibition in the Treatment of Male Pattern Hair Loss: Results of a Randomized Placebo-Controlled Study of Dutasteride Versus Finasteride

research The Importance of Dual 5α-Reductase Inhibition in the Treatment of Male Pattern Hair Loss: Results of a Randomized Placebo-Controlled Study of Dutasteride Versus Finasteride

215 citations , November 2006 in “Journal of The American Academy of Dermatology”

This study found that dutasteride increased scalp hair growth in men with male pattern hair loss, particularly at a 2.5 mg dose, and was more effective than finasteride over 24 weeks.

research A New Look at the 5-Alpha-Reductase Inhibitor Finasteride

137 citations , March 2006 in “Cns Drug Reviews”

This review explores finasteride's effects on neuroactive steroid levels and their potential influence on disorders like depression and alcohol withdrawal but reports no new clinical findings.

research Clinical Application of 5α-Reductase Inhibitors

46 citations , March 2001 in “Journal of endocrinological investigation”

This review discusses the use of 5α-reductase inhibitors, particularly finasteride, for treating conditions like benign prostatic hyperplasia, male baldness, and hirsutism, and reports no new clinical results.